Merck, Inc.
🇵🇭Philippines
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2409
- Registration Number
- NCT00365378
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00365443
Developing World Study for RotaTeq™ (V260-015)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7504
- Registration Number
- NCT00362648
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00362024
Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT00359671
Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 441
- Registration Number
- NCT00358670
Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 352
- Registration Number
- NCT00357279
Hyzaar Asia HEAALTH (0954A-950)
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 437
- Registration Number
- NCT00354991
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 262
- Registration Number
- NCT00350779
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 210
- Registration Number
- NCT00350623
© Copyright 2024. All Rights Reserved by MedPath